Patient-Focused Drug Development

What in the drug development process is most important to patients? The new FDA draft guidance on Patient-Focused Drug Development released September 30, 2019, provides quantitative and qualitative methods for sponsors to measure a patient’s experience with respect to disease burden and treatment. FDA invites comments until the end of the year.

Want to learn more?

Check out INSIDER ACCESS: Making Clinical Trials Work for Special Populations – our exclusive content for DIA Members. A full-length transcript is also available. Or download DIA's Considerations Guide to Implementing Patient-Centric Initiatives in Healthcare Product Development and DIA's Patient Engagement Study Findings from our Collaboration with the Tufts Center for the Study of Drug Development (CSDD).